Announced Date: 2024-08-29 (May 29, 2024)
Key Asset: Four GLP-1 Programs, HRS9531 (KAI-9531)、HRS-7535 (KAI-7535)、HRS-4729 (KAI-4729)
Licensor: Jiangsu Hengrui Pharmaceuticals(China)
Capital: BCLS Fund A, Atlas Ventures, RTW Fund, Lyra Capital
NewCo Name: Hercules CM NewCo, Inc. (established in 2024-05, USA; 2025-10-01, new company Kailera Therapeutics established）
.
Asset 1: HRS9531 (KAI-9531) (Injectable)
Modality: Peptide. Target: GLP-1/GIP receptor dual agonist.
Current Stage: Phase II, in China (Leading Asset)
.
Asset 2: HRS-7535 (KAI-7535)
Modality: Small Molecule. Target: GLP-1 receptor agonist. Oral tablet.
.
Asset 3: HRS9531 (KAI-9531) (0ral)
Modality: Peptide. Target: GLP-1/GIP receptor dual agonist.
.
Asset 4: HRS-4729 (KAI-4729)
Modality: Peptide. Target: GLP-1/GIP/Glucagon Receptor Tri-Agonist. Injection.
.
Scope of Authority:
Hengrui Pharmaceuticals granted the exclusive global rights to its drug portfolio to a newly established company under US private investment firm Bain Capital.
Hercules CM Newco will obtain the development, production, and commercialization rights worldwide, excluding China, for Hengrui’s GLP-1 diabetes and weight-loss drug.
.
Deal Detail:
Hengrui will be eligible to receive:
19.9% stake in Kailera.
.
Upfront payment and near-term payment of $110 million,
Development and regulatory milestone payments up to $200 million (base on HRS9531)
Sales milestone payments of up to $5.725 billion.
Total up to $6.035 billion.
Tiered royalties on net sales.
.
